Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) concerning potential violations of the federal securities laws and/or breaches of fid...
Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut...
Constellation Pharmaceuticals ([[CNST]] -0.1%) announced that the data from MANIFEST Phase 2 clinical trial for pelabresib (CPI-0610) in myelofibrosis ((MF)) were published online in association with the European Hematology Association ((EHA)) annual meeting. “We are particularly ...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...
NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Diamond S Shipping Inc. (NYSE:DSSI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties ...
Regional bank consolidation continues with three new bank deals announced last week. Extended Stay America catches a higher bid. Chamath Palihapitiya files for four new biotech-focused SPACs. For further details see: Merger Arbitrage Mondays: Extended Stay America Receiv...
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy Oral, once-daily 350mg dose selected for Phase 2 Enrollment of tumor-specific expansion cohorts is ongoing CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) ...
Shares of MorphoSys (NASDAQ: MOR) sank 11.5% this week as of the market close on Thursday. The decline stemmed from the German drugmaker's announcement on Wednesday that it plans to acquire Constellation Pharmaceuticals (NASDAQ: CNST) for $1.7 billion. MorphoSys also said th...
The stock of Constellation Pharmaceuticals (NASDAQ: CNST) was absolutely crushing it this week, up 70.6% as of the market close on Thursday. The catalyst behind this impressive performance was the announcement on Wednesday that German drugmaker MorphoSys (NASDAQ: MOR) plans ...
Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...